Re-Vana Therapeutics, a biotech start-up originating from Queens University Belfast in 2016, has recently secured a partnership with Boehringer Ingelheim to develop long-acting therapies for eye diseases. This collaboration, announced with an undisclosed upfront payment from Boehringer, has the potential to exceed $1 billion in value based on developmental milestones.
Combining Re-Vana’s extended-release drug delivery technology with innovative drug candidates, the companies aim to pioneer ‘first-in-class’ eye therapies. Re-Vana’s platform, utilizing a polymer injection for sustained drug release over six to twelve months, promises to reduce the need for frequent eye injections. With an internal pipeline featuring extended-release versions of prominent drugs like Eylea, Re-Vana is positioned as a key player in the biotech industry’s pursuit of revolutionary eye treatments.
Read more from biospace.com